JP7722989B2 - がんを治療するための方法及び組成物 - Google Patents

がんを治療するための方法及び組成物

Info

Publication number
JP7722989B2
JP7722989B2 JP2022527088A JP2022527088A JP7722989B2 JP 7722989 B2 JP7722989 B2 JP 7722989B2 JP 2022527088 A JP2022527088 A JP 2022527088A JP 2022527088 A JP2022527088 A JP 2022527088A JP 7722989 B2 JP7722989 B2 JP 7722989B2
Authority
JP
Japan
Prior art keywords
antibody
seq
fragment
composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022527088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500409A (ja
JP2023500409A5 (cg-RX-API-DMAC10.html
Inventor
シー． リアン，バートランド
ルイズ，ステイシー
ジョン ファリナ，クリストファー
Original Assignee
アブセントラ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブセントラ，エルエルシー filed Critical アブセントラ，エルエルシー
Publication of JP2023500409A publication Critical patent/JP2023500409A/ja
Publication of JP2023500409A5 publication Critical patent/JP2023500409A5/ja
Application granted granted Critical
Publication of JP7722989B2 publication Critical patent/JP7722989B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022527088A 2019-11-12 2020-11-12 がんを治療するための方法及び組成物 Active JP7722989B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934078P 2019-11-12 2019-11-12
US62/934,078 2019-11-12
PCT/US2020/060309 WO2021097146A1 (en) 2019-11-12 2020-11-12 Methods and compositions for treating cancer

Publications (3)

Publication Number Publication Date
JP2023500409A JP2023500409A (ja) 2023-01-05
JP2023500409A5 JP2023500409A5 (cg-RX-API-DMAC10.html) 2023-11-17
JP7722989B2 true JP7722989B2 (ja) 2025-08-13

Family

ID=75912868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022527088A Active JP7722989B2 (ja) 2019-11-12 2020-11-12 がんを治療するための方法及び組成物

Country Status (7)

Country Link
US (1) US12570731B2 (cg-RX-API-DMAC10.html)
EP (1) EP4058042A4 (cg-RX-API-DMAC10.html)
JP (1) JP7722989B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220131222A (cg-RX-API-DMAC10.html)
CN (1) CN115003319B (cg-RX-API-DMAC10.html)
CA (1) CA3160636A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021097146A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
CN121102464B (zh) * 2025-09-19 2026-08-11 深圳市中佳生物医疗科技有限公司 一种小分子调节剂通过促进epc细胞分化改善aki治疗的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510772A (ja) 2006-11-27 2010-04-08 パトリス リミテッド 新生細胞における新規なグリコシル化ペプチド標的
JP2012517216A (ja) 2009-02-09 2012-08-02 パトリス リミテッド Ｓａｍ−６変異体、標的および使用法
JP2012519706A (ja) 2009-03-06 2012-08-30 ジェネンテック， インコーポレイテッド 抗体製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500895A1 (en) * 2002-10-04 2004-04-15 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2240156A2 (en) 2007-12-28 2010-10-20 BioInvent International AB Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
US20090311271A1 (en) 2008-05-29 2009-12-17 Wyeth Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1)
US8729240B2 (en) 2010-04-28 2014-05-20 National University Corporation Hokkaido University Monoclonal antibody against oxidized low-density lipoprotein
WO2011160845A2 (en) * 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
CN105358708B (zh) * 2013-03-14 2024-07-16 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
US10858422B2 (en) * 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
WO2017210360A1 (en) * 2016-05-31 2017-12-07 Cardiovax, Llc Methods for diagnosing and treating systemic lupus erythematosus
EP3612563A1 (en) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019210207A2 (en) 2018-04-27 2019-10-31 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis
WO2019232070A1 (en) * 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of psoriasis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510772A (ja) 2006-11-27 2010-04-08 パトリス リミテッド 新生細胞における新規なグリコシル化ペプチド標的
JP2012517216A (ja) 2009-02-09 2012-08-02 パトリス リミテッド Ｓａｍ−６変異体、標的および使用法
JP2012519706A (ja) 2009-03-06 2012-08-30 ジェネンテック， インコーポレイテッド 抗体製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BBA - Molecular and Cell Biology of Lipids，2019年08月31日，Vol.1864, 158518，<https://doi.org/10.1016/j.bbalip.2019.158518>

Also Published As

Publication number Publication date
WO2021097146A1 (en) 2021-05-20
KR20220131222A (ko) 2022-09-27
EP4058042A1 (en) 2022-09-21
US20220403013A1 (en) 2022-12-22
JP2023500409A (ja) 2023-01-05
EP4058042A4 (en) 2023-12-27
CN115003319B (zh) 2026-03-31
WO2021097146A9 (en) 2021-08-05
US12570731B2 (en) 2026-03-10
CA3160636A1 (en) 2021-05-20
CN115003319A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
JP7575102B2 (ja) Ｍｕｃ１８に特異的な抗体
KR20200027971A (ko) 항-cd166 항체 및 이의 용도
EP3725802A2 (en) Antibodies to alpha-synuclein and uses thereof
WO2021042694A1 (zh) 抗vegf单域抗体及其应用
JP2025134815A (ja) クローディン１８．２を標的とする抗体－薬物コンジュゲート
JP2022522344A (ja) 高親和性抗ｍｅｒｔｋ抗体およびその使用
TWI710575B (zh) 人類抗-fgfr4抗體
AU2019316164A1 (en) Dosing regimen for BCMA-CD3 bispecific antibodies
JP7578289B2 (ja) Ｍｕｃ１８に特異的な抗体
JP2020523029A (ja) 抗ｌ１−ｃａｍ抗体およびその使用
WO2021082573A1 (zh) 抗il-4r单域抗体及其应用
KR20190003561A (ko) Alk7 결합 단백질 및 이들의 용도
EP4238989A1 (en) Anti-il5 nanoantibody and use thereof
TW202330620A (zh) 一種靶向ｒｏｒ１的抗體或其抗原結合片段及其應用
WO2025118472A1 (zh) 一种抗met/egfr双特异性抗体及其药物偶联物
US12570731B2 (en) Methods for treating cancer with an anti-apo B100 antibody
EP4491632A1 (en) Ror1-targeted binding molecule and use thereof
EP4047016A1 (en) Anti-tenascin-c (tnc) single-domain antibodies (nanobodies) and use thereof
CA3254345A1 (en) Ror1-targeted binding molecule and use thereof
WO2025133322A1 (en) Cnx antigen-binding molecules
WO2017174017A1 (zh) 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
HK40105152A (en) Antibodies specific to muc18
CN120018858A (zh) 恶性肿瘤的诊断、预后和治疗
HK40060752B (en) Antibodies specific to muc18
HK40060753B (en) Antibodies specific to muc18

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250731

R150 Certificate of patent or registration of utility model

Ref document number: 7722989

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150